GlassScriptPhysician profile
Khosrow Nafisi
NPI 1548289580
$13,185.52
in general payments reported to CMS, 2019-2025
54 companies · $1,897 in 2025
The $1,897 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,779 · 2020: $1,636 · 2021: $2,410 · 2022: $1,860 · 2023: $1,593 · 2024: $2,012 · 2025: $1,897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,499 · Education: $2.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,499.11 |
| Education | $2.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,801.74 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $1,504.17 | 2019-2025 | |
| Novo Nordisk INC | $1,115.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,090.01 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $937.27 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $855.15 | 2019-2023 | Jardiance |
| Amgen INC. | $788.87 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $773.91 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Kowa Pharmaceuticals America, INC. | $427.39 | 2019-2025 | Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $369.63 | 2019-2024 | Trintellix |
| Lucid Diagnostics INC. | $349.96 | 2021 | |
| Abbott Laboratories | $334.86 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Sanofi-Aventis U.S. LLC | $253.87 | 2019-2023 | |
| Astellas Pharma US INC | $229.72 | 2019-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.62 | 2019-2024 | Xifaxan, Trulance |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khosrow Nafisi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.